menu
Create
Copyright © 2024 Digital media blog website. All rights reserved.

Tag: asco 2022 conference

Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows du...

Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R...

  • havensmith

Braftovi shows a higher response rate in a triplet comb...

Braftovi shows a higher response rate in a triplet combination after adding...

  • havensmith

Closely watched Janssen and Legend Biotech's CAR-T cell...

Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrate...

  • havensmith

Genmab/Abbvie’s Epcoritamab achieves a 100% response ra...

Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients

  • havensmith

Gilead in trouble waters as Trodelvy shows below par re...

Gilead in trouble waters as Trodelvy shows below par response in 3L+ HR+/HE...

  • havensmith

Daiichi’s Patritumab, its third ADC making headway in H...

Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metas...

  • havensmith

Enhertu carving out a new space for itself in HER2 low...

Enhertu carving out a new space for itself in HER2 low patients. A major-la...

  • havensmith

Yet another failure in treating Small-Cell Lung Cancer...

Yet another failure in treating Small-Cell Lung Cancer as Roche's much-anti...

  • havensmith

Consistent Results Across All Sub-Groups Seen in the Ne...

Consistent Results Across All Sub-Groups Seen in the Newly Launched First i...

  • havensmith

Encouraging results of nivolumab + bevacizumab + FOLFOX...

Encouraging results of nivolumab + bevacizumab + FOLFOXIRI in patients with...

  • havensmith

Teclistamab, a soon-to-be-approved bispecific antibody,...

Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its pr...

  • havensmith

The PROs Further Support Durvalumab + Chemo in Becoming...

The PROs Further Support Durvalumab + Chemo in Becoming The New Standard of...

  • havensmith

Making Way For Immunotherapy In The GI Cancers, Durvalu...

Making Way For Immunotherapy In The GI Cancers, Durvalumab To Become The Ne...

  • havensmith

With modest efficacy, Neratinib Continues To Be A Poten...

With modest efficacy, Neratinib Continues To Be A Potential Treatment Optio...

  • havensmith

Daiichi’s novel HER3 ADC has Shown To Have a Spark in H...

Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post succ...

  • havensmith

Connect With Community